<DOC>
	<DOCNO>NCT00197015</DOCNO>
	<brief_summary>This study evaluate immune response safety GSK Biologicals 2-dose inactivate hepatitis A vaccine administer measles/mumps/rubella vaccine varicella ( chickenpox ) vaccine child young 15 month age . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Immunogenicity &amp; Safety Hepatitis A Vaccine Co-admin With Measles/Mumps/Rubella &amp; Varicella Vaccine Children</brief_title>
	<detailed_description>An open , control comparison Havrix™ administer alone MMR II Varivax™ . The three group evaluate : 1 ) Havrix™ alone , 2 ) Havrix™ + MMR II Varivax™ 3 ) MMR II Varivax™ follow Havrix™ one month later .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Rubella</mesh_term>
	<mesh_term>Chickenpox</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects whose parents/guardians believe investigator willing comply requirement protocol A male female child 12 13 month age time entry Enrollment Phase Written inform consent obtain parent guardian subject , Free obvious health problem establish medical history historydirected physical examination enter study , Parents/guardian subject must telephone able contact telephone Use investigational nonregistered drug vaccine study vaccine ( ) within 42 day precede first dose study vaccine , plan use study period , Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior vaccination plan administration time study period . ( For corticosteroid , mean prednisone , equivalent , ≥0.5 mg/kg/day . Inhaled , nasal topical steroid allow . ) Planned administration administration vaccine foreseen study protocol period 31 day 31 day dose study vaccine ( ) . Previous vaccination hepatitis A , History hepatitis A , Known exposure hepatitis A , Previous vaccination measles , mumps , rubella and/or varicella , History measles , mumps , rubella and/or varicella , Known exposure measles , mumps , rubella and/or varicella within 30 day prior start study , Planned chronic use salicylates 6week period follow administration dos study vaccine ( ) , Any confirm suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection , A family history congenital , hereditary infectious immunodeficiency parental risk factor HIV infection , History allergic disease/reactions hypersensitivity likely exacerbate component HavrixTM , MMRII VARIVAXTM , include 2phenoxyethanol , neomycin gelatin , History anaphylactic anaphylactoid reaction egg protein , History hypersensitivity/allergic reaction latex . Note : The tip cap rubber plunger HavrixTM needleless prefilled syrinx contain dry natural latex rubber . Major congenital defect serious chronic illness , Active untreated tuberculosis , History significant blood dyscrasias History neurologic disorder ( history febrile seizure associate underlying neurological disorder exclude subject ) Acute disease time vaccination Administration immunoglobulins and/or blood product within three month prior first dose study vaccine plan administration time entire study period</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>13 Months</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>